The US Probiotic Industry Has A Dirty Little Secret
America’s supplement market operates on an infrastructure most consumers have never heard of. A handful of contract manufacturers produce the vast majority of what gets sold under hundreds of different brand names at wildly different price points
The premium branding, the DTC subscription model, the clinical-sounding language – almost none of it reflects what’s actually in the capsule.
Here is an experiment you can run right now from your kitchen counter.
Find whatever probiotic you’re currently taking. Read the label. Note the strains: Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus rhamnosus.
Note the CFU count – maybe 30 billion, maybe 50 billion. Note the delivery mechanism: a vegetable capsule, perhaps with an enteric coating, in a matte-finish amber bottle that looks expensive.
Now go to Amazon and search “probiotic supplement.” Click through a dozen listings. Read the labels.
You’ll notice something. The products carry different names. They have different founders with different stories. They’re priced from $12 to $80 a bottle.
Their marketing ranges from budget to polished to impressively scientific. But the strains are often identical. The CFU counts sit in the same range. The capsule format is the same. The language – “clinically studied strains,” “advanced formulation,” “gut health support” – is essentially interchangeable.
This is not coincidence. It is the supply chain.
And understanding it will permanently change how you think about the $50 you’re spending every month on gut health.
How the Probiotic Market Actually Works
The American supplement industry operates through a manufacturing architecture that is entirely standard – and entirely invisible to consumers.
At the top sits a small number of global ingredient suppliers that develop, patent, manufacture, and sell the probiotic strains themselves. Novonesis A/S – formed by the 2024 merger of Chr. Hansen and Novozymes, both Danish biotech giants – ADM, International Flavors & Fragrances, Kerry Group, and Lallemand collectively dominate the upstream probiotic ingredient market.
These are not brands you’ll find at Whole Foods or on Amazon. They are industrial ingredient companies. They supply bacterial cultures – freeze-dried powders – to the next tier of the supply chain.
That tier is the contract manufacturer.
Contract manufacturers take bulk cultures and turn them into finished products: blending strains, filling capsules, applying coatings, bottling, and applying whatever label the client provides.
In the United States, companies like Vitaquest International in New Jersey – which produces over 4,000 custom formulas for more than 500 brands – Nutracap Labs in Georgia, NOW Foods in Illinois, and Bactolac Pharmaceutical in New York manufacture probiotic supplements on behalf of dozens, sometimes hundreds, of different brand identities simultaneously.
Vitaquest creates and produces more than 4,000 custom formulas for more than 500 brands in over 50 countries, via every important commercial channel. They describe their private label service explicitly: “private label manufacturing involves purchasing generic, pre-existing supplement formulas and selling them under your own brand name.”
Read that sentence carefully. Pre-existing formulas. Sold under your own brand name.
The brand owner – the company whose name is on the bottle, whose founder appears in the Instagram Reels, whose subscription box arrives with a handwritten note about microbiome science – may have no manufacturing capability whatsoever.
No laboratory. No microbiologists on staff. No fermentation equipment. They have a brand identity, a Shopify store, a digital marketing budget, and a contract with a manufacturer who handles everything from formulation to fulfilment.
This is legal. It is standard. And it is, for consumers paying premium prices on the basis of implied proprietary expertise, a significant deception by omission.
The DTC Probiotic Brand: What You’re Actually Buying
The direct-to-consumer probiotic subscription model has been one of the great marketing innovations of the 2010s and 2020s. Seed, Ritual, Pendulum, Care/of, Onnit, Roman – the names shift, the aesthetic is consistent: clean design, founder-led storytelling, references to microbiome science, a subscription that auto-renews and arrives in recyclable packaging with an insert explaining why this particular formulation represents a breakthrough in gut health.
The founder is typically not a microbiologist. They are an entrepreneur who identified a high-margin category, contracted a manufacturer, developed a brand identity, and built a customer acquisition engine.
Nothing about this is illegal. It is, in fact, standard consumer packaged goods practice applied to the supplement category.
But the premium that these brands charge – and in some cases it is substantial, $50 to $80 per month for a subscription probiotic – is priced against the implied value of proprietary science that, in most cases, does not exist at the product level.
Seed’s DS-01 Daily Synbiotic, for example, is sold at $49.99 per month and marketed with genuinely sophisticated scientific communication – references to specific strains, to clinical research, to the distinction between probiotic and postbiotic mechanisms.
The science communication is better than most. But the strains in the product are sourced from the same upstream ingredient suppliers that supply the broader market. The “2-in-1 nested capsule” delivery system is a real innovation – outer and inner capsule technology designed to protect organisms through the stomach.
Whether that innovation is worth $49.99 per month compared to a $15 enteric-coated equivalent is a question the marketing is not designed to help you answer.
Ritual’s Synbiotic+ follows the same pattern: sophisticated branding, subscription model, $45 per month, strains sourced from ingredient suppliers. The product contains a prebiotic and a postbiotic component alongside the probiotic strain – a genuine formulation choice with some scientific rationale.
But the specific organisms are not proprietary to Ritual. They are sourced from the same industrial ingredient ecosystem that supplies products at every price point.
The Upstream Reality: A Few Companies Supply Almost Everything
The upstream concentration of the probiotic ingredient market creates a consequence that flows directly into the consumer’s capsule: the strains in the vast majority of American probiotic supplements trace back to a very small number of sources.
Novonesis – the Chr. Hansen/Novozymes merger entity – owns some of the world’s most clinically documented probiotic strains: LGG (Lactobacillus rhamnosus GG), BB-12 (Bifidobacterium animalis subsp. lactis), and LA-5 (Lactobacillus acidophilus).
These strains are licensed to hundreds of brands simultaneously. The strain in your premium subscription capsule and the strain in the CVS store-brand capsule may be identical – both licensed from the same Danish company, processed by different contract manufacturers, priced at 4x multiples for reasons that have nothing to do with the organism inside.
IFF – International Flavors & Fragrances, a $22 billion industrial conglomerate whose primary business involves making things smell and taste good – owns the HOWARU portfolio of clinically studied probiotic strains: HN001, HN019, NCFM, Bi-07, Bl-04.
These strains appear in products across the price spectrum, from high-end functional medicine brands to Costco bottles. IFF supplies them all.
The combined share of the top five probiotic ingredient companies accounts for around 55 percent of the global probiotic ingredients market, with Chr. Hansen, DSM, and Lallemand leading industry development.
Fifty-five percent of the global ingredient supply, controlled by five companies. The hundreds of brands competing for your attention in the supplement aisle are largely selling variations of the same upstream raw material, differentiated by branding, marketing spend, and the particular combination of strains and doses their contract manufacturer has assembled.
The Amazon White-Label Explosion
The most visible expression of the white-label reality is the Amazon probiotic market, which has become one of the most extraordinary examples of commodity supplement selling in retail history.
Search “probiotic supplement” on Amazon today and you will find thousands of results. Many have nearly identical formulations: 50 billion CFU, 10 or more strains, vegetable capsule, refrigeration not required.
The brand names are generic – NewRhythm, Nature’s Bounty, Physician’s Choice, Culturelle Pro Strength and dozens of others. The reviews are often substantial. The prices range from $10 to $40 for essentially equivalent products.
A meaningful proportion of these products were made by the same contract manufacturers, using the same or equivalent strain sources, differentiated by label design and price point rather than by any meaningful scientific distinction.
The Amazon algorithm rewards products with strong review velocity and competitive pricing, not products with superior formulations. The result is a marketplace in which the relationship between price and quality is essentially random.
Products distributed through platforms such as Amazon face a particular challenge: warehouse temperatures can exceed 100°F during summer months, so selecting resilient strains is essential. Most Amazon probiotic listings do not disclose how their products are stored in Amazon fulfilment centres.
The refrigeration-sensitive strains that some of these products contain may have experienced significant thermal stress before they reach the consumer.
The Amazon probiotic market is, in its current form, a buyer-beware environment operating under the assumption that buyers know what they’re looking for. Most don’t, because the information required to make an informed choice is not provided on the listing.
The Corporate Consolidation Nobody Talks About
The premium and mass-market ends of the US probiotic supplement market are, in many cases, owned by the same parent companies – a consolidation that has systematically blurred the distinction between brands that appear to be competitors.
Garden of Life – sold at Whole Foods, positioned as organic, whole-food based, “doctor formulated,” marketed to health-conscious consumers willing to pay a premium – is a brand of Nestlé Health Science.
Nestlé Health Science, whose parent company is the world’s largest food corporation, also partnered with Seres Therapeutics to commercialise Vowst, the FDA-approved pharmaceutical FMT product.
The same corporation sells you the $4 Nestlé yogurt, the $35 Garden of Life probiotic, and stands to benefit from the $17,500 pharmaceutical FMT product. The “natural” positioning of Garden of Life is a brand identity owned by a corporation with no particular commitment to natural philosophy.
Renew Life – “America’s #1 digestive health and cleanse brand,” sold in every major pharmacy chain – is owned by Church & Dwight, which also manufactures Arm & Hammer baking soda, OxiClean, Trojan condoms, and First Response pregnancy tests.
Church & Dwight is a $5 billion consumer goods corporation. Its Renew Life subsidiary positions itself as a specialist gut health brand with deep clinical expertise. The manufacturing economics of Renew Life products benefit from Church & Dwight’s scale and supply chain infrastructure – the same infrastructure that makes Arm & Hammer competitive at commodity pricing.
Nature Made – which describes itself as “the largest vitamin and supplement manufacturer in the United States” – launched a new probiotic line in March 2025. Nature Made is owned by Pharmavite, a subsidiary of Otsuka Pharmaceutical, a Japanese multinational pharmaceutical company.
Your “natural” supplement brand is a product line of a Japanese pharma giant.
None of this is disclosed on the label. None of it is required to be.
DSHEA: The Law That Made All of This Possible
The regulatory architecture that permits this market to operate as it does is DSHEA – the Dietary Supplement Health and Education Act of 1994. Passed with heavy industry lobbying at a moment when the natural health movement was asserting its right to access supplements without pharmaceutical-level regulation, DSHEA created the framework under which the supplement industry has operated – and flourished – ever since.
Under DSHEA, the FDA cannot require manufacturers to conduct pre-market testing to prove that their supplements contain only advertised ingredients. Instead, FDA can review new dietary ingredients before they enter the market by requiring manufacturers to notify FDA of what the ingredient is and why they expect it to be safe.
DSHEA allows widespread market access without universal pre-market safety review, producing both consumer choice and regulatory challenges. The argument that the FDA does not regulate supplements effectively rests on the claim that DSHEA removed pre-market approval requirements, leaving the agency largely reactive and dependent on voluntary industry compliance and post-market enforcement.
No pre-market testing.
No independent verification that the product contains what the label claims.
No requirement to disclose who manufactured the product, where the strains were sourced, or what the relationship is between the clinical evidence cited in marketing materials and the specific product being sold.
The FDA’s enforcement authority is post-market — it can act after a product is on sale and evidence of harm or mislabelling emerges. Even when FDA has issued a public notice about unsafe dietary supplements and manufacturers have voluntarily recalled their supplements, many of these harmful products remain on the market.
The system is reactive, complaint-driven, and systematically under-resourced relative to a market selling $6 billion of probiotic products annually in the United States alone.
The FTC has authority over advertising claims. It exercises that authority selectively – the Dannon settlement of 2010 being the most prominent probiotic example, at $45 million for unsubstantiated benefit claims.
For every Dannon, there are thousands of smaller brands making claims that are never examined.
The supplement industry’s trade associations – the Council for Responsible Nutrition, the Natural Products Association – lobby actively against any strengthening of pre-market requirements.
Their argument is that DSHEA strikes the right balance between access and oversight. Their members’ revenue depends on a system that allows products to reach market without independent verification of their contents.
This is taken from a long document. See the rest here substack.com
Bold emphasis added
Header image: Consumer Lab
Tom
| #
Name your poisons…vaccines, drugs or supplements.
Reply